Orexo experienced a challenging quarter with weaker-than-expected sales for Zubsolv and the DTx offering. The flagship pharma project, OX124, did not receive fast-track approval, delaying its potential launch until late 2023. Consequently, we lower our estimates and cut our DCF-based fair value range to SEK 66-85 (72-91).
LÄS MER
